Definium Therapeutics, Inc.

NASDAQ:DFTX

Biotechnology

Healthcare
$29.12 -1.67%

-$0.41 today

Market cap
$3.99B
Beta
2.38
P/E (TTM)
-11.0
EPS (TTM)
-$2.18
52W Low $12.88High $26.15

Volume 1.91M

Average 2.67M

DFTX Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Definium Therapeutics, Inc.NASDAQ: DFTX

Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026

Depreciation & amortization remains negative

Q3 FY2026 depreciation & amortization was $0, compared with $6.75K a year earlier. Trailing-twelve-month depreciation & amortization was $631K.

Context

  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $157.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMSep 2026
$631K-13.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Depreciation & Amortization vs competitors

How DFTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -13.8% is the 5th highest of 10, against a peer median of -16.4%.
DFTX Competitors
Depreciation & Amortization for DFTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$9.94M USD+16.8%+27.2%1.3%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$1M USD+7.4%+307.8%5.0%
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$631K USD-13.8%——
ANROAlto Neuroscience, Inc.LTM Mar 2026$605K USD+5.0%+24.6%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$574K USD-20.3%+0.2%—
GHRSGH Research PLCLTM Mar 2026$350K USD+12.5%+92.4%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$325.5K USD—+443.4%—
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$133K USD-16.4%-30.6%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$59K USD-90.6%-29.5%—
ATHEAlterity Therapeutics LimitedFY2025A$28.31K AUD-19.9%-19.5%0.5%
NERVMinerva Neurosciences, Inc.LTM Jun 2026$2.72K USD-71.9%-13.9%—
Peer median (excluding DFTX) —-16.4%+12.4%1.3%

Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue003.16M527K0
Gross Profit00(3.16M)(527K)0
Gross Margin—————
Research & Development34.79M36.17M48.96M65.3M117.67M
Selling, General & Admin59.07M30.16M41.74M38.62M48.64M
Operating Expenses93.85M66.33M90.7M103.39M166.31M
Depreciation & Amortization2.62M3.18M3.16M527K0
EBITDA(91.22M)(52.12M)(92.57M)(105.87M)(178.31M)
EBITDA Margin—————
Operating Income(93.85M)(66.33M)(93.87M)(103.92M)(166.31M)
Operating Margin—————
Interest Income01.5M5.58M11.56M10.96M
Interest Expense359K1.5M920K2.28M5.48M
Other Income / Expenses(339K)9.54M(1.87M)(4.76M)(17.48M)
Income Before Tax(94.19M)(56.8M)(95.73M)(108.68M)(183.79M)
Pre-Tax Margin—————
Income Tax Expense(1.16M)0000
Net Income(93.04M)(56.8M)(95.73M)(108.68M)(183.79M)
Net Margin—————
EPS (Basic)(3.40)(1.53)(2.44)(1.54)(2.06)
EPS (Diluted)(3.40)(1.53)(2.44)(0.15)(2.06)
Weighted Avg Shares27.38M30.86M39.16M70.46M89.33M
Weighted Avg Shares (Diluted)27.38M30.86M39.16M704.61M89.33M

Definium Therapeutics, Inc.

NASDAQ:DFTX

Intrinsic Alpha fair value

Locked

Current Price

$29.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.